Back

Co-activation of selective nicotinic acetylcholine receptor subtypes is required to reverse hippocampal network dysfunction and prevent fear memory loss in Alzheimer's disease

Lee, R.; Kim, G.; Kim, S.

2024-07-11 neuroscience
10.1101/2024.07.08.602576 bioRxiv
Show abstract

Alzheimers disease (AD) is characterized by hippocampal hyperexcitability and cognitive impairment, in part due to {beta}-amyloid (A{beta})-induced suppression of GABAergic interneuron activity. Enhancing hippocampal inhibition is therefore considered protective, but inhibitory interneurons are highly diverse and not uniformly affected by A{beta}. We previously showed that A{beta} selectively inhibits 7- and 4{beta}2-nicotinic acetylcholine receptors (nAChRs), but not 3{beta}4-nAChRs, on hippocampal inhibitory interneurons, leading to excitatory neuron hyperactivity, and that co-activation of 7- and 4{beta}2-nAChRs reverses these effects. Here, we demonstrate that 7- and 4{beta}2-nAChRs predominantly regulate cholinergic synaptic activity in parvalbumin-positive (PV+) and somatostatin-positive (SST+) interneurons, respectively. Systemic co-stimulation of these receptors is required to reverse hippocampal hyperexcitability, fear learning-related oscillatory dysfunction, and fear memory loss, and reduce A{beta} pathology in AD model mice, indicating that coordinated activation of PV+ and SST+ interneurons via co-activation of 7- and 4{beta}2-nAChRs is required for optimal therapeutic benefit. TeaserCo-activation of selective cholinergic receptors is required to protect Alzheimers disease.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.